Ask Our Doctors – Archive
Our Medical Directors are outstanding physicians that you will find to be very personable and compassionate, who take care to ensure that you have the most cutting-edge fertility treatments at your disposal. This is your outlet to ask your questions to the doctors.
I am 30 years old. I had a FET on 5/19 with PGT-A testing. I had my first Hcg test done on 5/27 and it was 98. I had a second Hcg draw on 6/1 and it was 1120. Everything was looking great.
I had my first ultrasound on 6/14 and all that was visible was a gestational sac (11.7 mm) and a yolk sac (4.5 mm). My doctor was please with the ultrasound and assumed I was just a little earlier than expected. This does not make sense to me because the dates are exact with IVF. He wants to see me next week for another scan. I feel that she should have at least been a fetal pole at this point. Is it possible for this to be a normal pregnancy and a just a little behind?
Yes! It is possible that this could turn out to be a normal pregnancy!
Good luck!
Geoff Sher
I don’t think my question went through- What are your thoughts on the covid vaccine for pregnant women who had immune-related subfertility? I have Hashimotos and celiac disease with positive ANA. I am 21 weeks pregnant. Would you recommend the covid shot or could that cause some kind of immune flare up that could harm the baby?
It probably wont do any harm. But personally, I would delay the vaccination until after the baby is born. But discuss with your personal OB!
Good luck!
Geoff Sher
Hi Dr.
We did a FET of a PGT tested euploid embryo on 5/27.
Got a home hcg test positive on 6/6 at 10dpt. Day 11 initial beta HCG was 54, day 13 -94, day 15-150, day 16-207,and day 19-587.
After 15dpt result of 150, our doctor advised to stop meds (prior to ultrasound confirmation, which we did for 1.5 days out of fear of complications explained to us). Had an independent beta HCG drawn following morning 6/12 (16dpt) which showed 207 HCG. No symptoms of cramping or bleeding. We decided to resume meds (estrogen TID and PIO IM at bedtime) pending repeat beta and ultrasound on 6/15.
Based on day 19 (6/15) beta HCG of 587 and ultrasound done same day ( which showed no sign of sac or embryo), our doctor is telling us that this is not a viable pregnancy and we should stop estrogen/progesterone as at this point it’s either a pregnancy of unknown origin or an ectopic pregnancy not yet seen.
We have read that in 15% of pregnancies, slow rising HCG could be normal and that rise does not necessarily need to be every 48 hours and/or 100% to be considered viable. If we were to go by those metrics, the sudden increase to 587 could indicate we would be over 1,000 in 2 days at 5w6d. And which is the lowest beta HCG the doctor told us is something would be visible on ultrasound with anyway. Also, we were under impression sometimes nothing is visible on u/s until 6 weeks gestation. Through this entire time, at home urine pregnancy tests have been consistently coming back positive, with darkening test lines. Finally, the doctor mentioned to us that there’s no such thing as late implantation with IVF, which we understand – but my wife felt like her implantation cramps occurred and continued later.
Between those facts and questions, we are left wondering if it’s actually too early to call it, confused about the facts and circumstances, and feeling like it’s too early to stop but of course not wanting to prolong the inevitable and cause greater harm to my wife and her health.
Any feedback would be helpful! Thank you in advance!
It could be too early still. I would continue meds, give it 10 days and do an US for a definitive answer. Your OB should however, be watching for the unlikely event of an ectopic (tubal) pregnancy.
Geoff Sher
What are your thoughts on pregnant women who have immune-related infertility getting the covid shot?
I have no problem with it, but I personally advise against taking the shot during pregnancy and would wait at least 1 month after the vaccination before trying to conceive.
Geoff sher
I am 39 years old and in the mist of my 1st IVF cycle due to SIN of my tube and MFI. I started BCP on April 19th, had a hysteroscopy on May 20th . Stopped BC on 6/7 and went in for my first baseline u/s on 6/9. RE said several small follicles on both ovaries and we was clear to push forward with IVF. I have regular cycles every 28 days and my protocol is as follows : Lupron 5 units, Follistim 350 +1 and Menopur 1 vial. I went in today for my 2nd U/S and no follicles on left ovaries and 5 follicles on right ovaries. My RE was disappointed and stated that this was not what he expected and asked was I giving my injections correctly. They want me back in 3 days and also awaiting bloodwork from today. My bloodwork from 6/9 was Total Estradiol- 23.63 pg/mL and Progesterone Level-0.32 ng/mL. The only thing I can think of that I did out of the ordinary was get acupuncture yesterday for the 1st time. Any suggestions? He kept me at the same dosage until I return on Friday and stated that he may have to call in another prescription for me.
It sounds as if you might have severely diminished ovarian reserve and if so, you would in my opinion need a an aggressive but individualized protocol for ovarian stimulation.
It is primarily the egg (rather than the sperm) that determines the chromosomal integrity (karyotype) of the embryo, the most important determinant of egg/embryo competency”. A “competent” egg is therefore one that has a normal karyotype and has the best potential to propagate a “competent” embryo. In turn, a “competent embryo is one that possesses the highest potential to implant and develop into a normal, healthy, baby.
When it comes to reproductive performance, humans are the least efficient of all mammals. Even in young women under 35y, at best only 1 out of 2 eggs are chromosomally numerically normal (euploid). The remained have an irregular number of chromosomes (aneuploid) and are thus “incompetent”. The incidence of egg aneuploidy increases with age such by age 39 years, 3 in 4 are competent, and by the mid-forties, less 8 to 9 out of 10 are aneuploid. The fertilization of an aneuploid egg will inevitably lead to embryo aneuploid and an aneuploid embryo cannot propagate a normal pregnancy
Within hours of the spontaneous pre-ovulatory luteinizing hormone (LH) surge, and also following administration of the human chorionic gonadotropin (hCG) “trigger” shot (given to induce ovulation after ovarian stimulation with fertility drugs), the egg embarks on a rapid maturational process that involves halving of its 46 chromosomes to 23. During this process, (known as meiosis) 23 chromosomes are retained within the nucleus of the egg while the remaining (now redundant) 23are expelled, enveloped by a thin membrane. This small structure comes to lie immediately below the “shell” of the egg (the zona pellucida) and is known as the 1st polar body or PB-1. The spermatozoon, in the process of its maturation also undergoes meiosis at which time it too reduces its chromosomes by half. Thus in the process of fertilization the sperm divides into two separate functional gametes, each containing 23 chromosomes such that with subsequent fertilization, the 23 chromosomes in the egg, fuse with the 23 chromosomes of the mature sperm resulting in the development of an embryo that has 46 chromosomes (the normal human genome) comprising a combination of the genetic material from both partners. For the embryo to have exactly 46 chromosomes (the euploid number), both the mature egg and mature spermatozoon must contain exactly 23 chromosomes. Only euploid embryos are “competent” (capable of developing into healthy babies). Those with an irregular number of chromosomes (aneuploid embryos) are “incompetent” and are incapable of developing into healthy babies. While embryo “incompetence” can result from either egg or sperm aneuploidy, it usually stems from egg aneuploidy. However, in cases of moderate or severe male factor infertility, the sperm’s contribution to aneuploidy of the embryo increases significantly.
While embryo ploidy (numerical chromosomal integrity) is not the only determinant of its “competency, it is by far the most important and in fact is rate-limiting factor in human reproduction. It is causal in most cases of “failed implantation” which in turn is responsible for most cases of failed IVF. It causes early miscarriages and is responsible for many chromosomal birth defects such as X-monosomy and Down’s syndrome. . In most cases, embryos that develop too slowly as well as those that grow too fast (i.e. ones that by day 3 post-fertilization comprise fewer than 6 cells or more than 9 cells) and/or embryos that contain a large amount of cell debris or “fragments” are usually aneuploid and are thus “incompetent”. Additionally, embryos that fail to survive in culture to the blastocyst stage are also almost always aneuploid/”incompetent”. At a certain point in the later stage of a woman’s reproductive career, the number of remaining eggs in her ovaries falls below a certain threshold, upon which she is unable to respond optimally to fertility drugs. Often times this is signaled by a rising day 3 blood follicle stimulating hormone (FSH) level. Such women with diminishing ovarian reserve produce fewer eggs in response to ovarian stimulation. While diminished ovarian reserve is most commonly encountered in women over 40 years of age it can and indeed sometimes does occur in much younger women. A few important (but often overlooked concepts should be considered in this regard: 1. Age: It is advancing chronologic age and NOT declining ovarian reserve (as evidenced by abnormal blood AMH or FSH that results in an increased incidence of egg/embryo “incompetence” due to aneuploidy 2. DOR: The ovaries and developing eggs of women with diminished ovarian reserve (regardless of age) are highly susceptible to the adverse effect of excessive Luteinizing Hormone (LH)-induced overproduction of male hormones (mainly testosterone). A little testosterone produced by the ovary promotes normal follicle growth and orderly egg development but too much testosterone has the opposite effect. That is why (especially in women with diminished ovarian reserve who often have high LH and increased ovarian testosterone production , the use of ovarian stimulation protocols that fail to down-regulate LH production prior to initiating stimulation with gonadotropins, often prejudices egg/embryo quality and IVF outcome. Simply stated, while age is certainly the most important factor in determining the incidence of egg/embryo aneuploidy, women with diminished ovarian reserve (regardless of their age), unless they receive customized/individualized protocols of ovarian stimulation are less likely to propagate euploid (competent) eggs/embryos.
Selection of the ideal protocol for controlled ovarian stimulation: While NOTHING can be done to lower the incidence of age related aneuploidy, it is indeed possible to avoid a further increase in egg/embryo aneuploidy by individualizing the protocols of ovarian stimulation used.
•My preferred protocols for women who have relatively normal ovarian reserve:
a)The conventional long pituitary down regulation protocol: BCP are commenced early in the cycle and continued for at least 10 days. Starting 3 days before the BCP is to be discontinued, it is overlapped with an agonist such as Lupron 10U daily for three (3) days and continued until menstruation begins (which should ensue within 5-7 days of stopping the BCP). At that point an US examination is done along with a baseline measurement of blood estradiol to exclude a functional ovarian cyst. Simultaneously, the Lupron dosage is reduced to 5U daily and an FSH-dominant gonadotropin such as Follistim, Puregon or Gonal-f daily is commenced for 2 days. On the 3rd day the gonadotropin dosage is reduced and a small amount of daily menotropin (Menopur 75U daily) is added. Daily ultrasound and blood estradiol measurements are done starting on the 7th or 8th day of gonadotropin administration and continued until daily ultrasound follicle assessments indicate that most follicles have fully developed. At this point egg maturation is “triggered” using an intramuscular injection of 10,000U hCG. And an egg retrieval is scheduled for 36h later.
b)The agonist/antagonist conversion protocol (A/ACOP): This is essentially the same as the conventional long down regulation protocol (as above), except that with the onset of post-BCP menstruation, the agonist is supplanted by daily administration of a GnRH antagonist (e.g. Ganirelix, Cetrotide or Orgalutron) at a dosage of 125mcg daily until the day of the hCG trigger
•My preferred protocol for women who have relatively diminished ovarian reserve (DOR):
When it comes to women who have DOR I favor the use of the A/ACP, adding supplementary human growth hormone (HGH). In some cases where the DOR is regarded as severe, I also augment the process with estrogen priming, preferring twice weekly intramuscular administration of estradiol valerate (Delestrogen), starting with the commencement of antagonist injection and continuing for 1 week before commencing gonadotropins and continued until the hCG “trigger. I further recommend that such women be offered access to preimplantation genetic screening (PGS) for4 embryo selection and in some cases, for embryo banking (stockpiling). This is followed in a later hormone replacement cycle with the selective transfer of up to two (2) PGS-normal, euploid blastocysts. In this way we are able to capitalize on whatever residual ovarian reserve and egg quality might still exist and thereby “make hay while the sun still shines” , significantly enhancing the opportunity to achieve a viable pregnancy
•The following Ovarian stimulation protocols are in my opinion best avoided in women with DOR:
a)Microdose agonist (e.g. Lupron) “flare” protocols
b)High doses of LH/hCG-containing fertility drugs (E.G. Menopur).
c)Protocols that incorporate supplementation with male hormones (e.g. testosterone)
d)Supplementation with DHEA
e)Clomiphene citrate or Letrozole which cause an elevation in LH and thus increase ovarian male hormone (testosterone and androstenedione output.
f)“Triggering” egg maturation using too low a dosage of hCG (e.g. 5,000U rather than 10,000U) or Ovidrel e.g. 250mcg of Ovidrel rather than 500mcg)
g)“Triggering” women who have large numbers of follicles using an agonist such as Lupron, Superfact or Buserelin.
•Preimplantation Genetic Screening (PGS):
The introduction of preimplantation genetic screening (PGS) for the first time permits identification of all the chromosomes in the egg and embryo such that we can now far better identify “competent” (euploid) embryos for selective transfer to the uterus. This vastly improves the efficiency and success of the IVF process. This additional tool has better equipped us to manage cases with DOR. In my opinion, next generation gene sequencing (NGS), currently represents the most reliable method for performing PGS
Please visit my new Blog on this very site, www. SherIVF.com, find the “search bar” and type in the titles of any/all of the articles listed below, one by one. “Click” and you will immediately be taken to those you select. Please also take the time to post any questions or comments with the full expectation that I will (as always) respond promptly
•Controlled Ovarian Stimulation (COS) for IVF: Selecting the ideal protocol
•IVF: Factors Affecting Egg/Embryo “competency” during Controlled Ovarian Stimulation(COS)
•The Fundamental Requirements For Achieving Optimal IVF Success
•Ovarian Stimulation for IVF using GnRH Antagonists: Comparing the Agonist/Antagonist Conversion Protocol.(A/ACP) With the “Conventional” Antagonist Approach
•Anti Mullerian Hormone (AMH) Measurement to Assess Ovarian Reserve and Design the Optimal Protocol for Controlled Ovarian Stimulation (COS) in IVF.
•The “Biological Clock” and how it should Influence the Selection and Design of Ovarian Stimulation Protocols for IVF.
• A Rational Basis for selecting Controlled Ovarian Stimulation (COS) protocols in women with Diminished Ovarian Reserve (DOR)
•Diagnosing and Treating Infertility due to Diminished Ovarian Reserve (DOR)
•Controlled Ovarian Stimulation (COS) in Older women and Women who have Diminished Ovarian Reserve (DOR): A Rational Basis for Selecting a Stimulation Protocol
•Human Growth Hormone Administration in IVF: Does it Enhances Egg/Embryo Quality and Outcome?
•The BCP: Does Launching a Cycle of Controlled Ovarian Stimulation (COS). Coming off the BCP Compromise Response?
•Blastocyst Embryo Transfers Should be the Standard of Care in IVF
•Frozen Embryo Transfer (FET) versus “Fresh” ET: How to Make the Decision
•Frozen Embryo Transfer (FET): A Rational Approach to Hormonal Preparation and How new Methodology is Impacting IVF.
•Staggered IVF: An Excellent Option When. Advancing Age and Diminished Ovarian Reserve (DOR) Reduces IVF Success Rate
•Embryo Banking/Stockpiling: Slows the “Biological Clock” and offers a Selective Alternative to IVF-Egg Donation.
•Preimplantation Genetic Testing (PGS) in IVF: It Should be Used Selectively and NOT be Routine.
•Preimplantation Genetic Sampling (PGS) Using: Next Generation Gene Sequencing (NGS): Method of Choice.
•PGS in IVF: Are Some Chromosomally Abnormal Embryos Capable of Resulting in Normal Babies and Being Wrongly Discarded?
•PGS and Assessment of Egg/Embryo “competency”: How Method, Timing and Methodology Could Affect Reliability
•Treating Out-of-State and Out-of-Country Patients at Sher-IVF in Las Vegas:
•Traveling for IVF from Out of State/Country–
•A personalized, stepwise approach to IVF
•How Many Embryos should be transferred: A Critical Decision in IVF.
•The Role of Nutritional Supplements in Preparing for IVF
•Premature Luteinization (“the premature LH surge): Why it happens and how it can be prevented.
•IVF Egg Donation: A Comprehensive Overview
___________________________________________________
ADDENDUM: PLEASE READ!!
INTRODUCING SHER FERTILITY SOLUTIONS (SFS)
Founded in April 2019, Sher Fertility Solutions (SFS) offers online (Skype/FaceTime) consultations to patients from > 40 different countries. All consultations are followed by a detailed written report presenting my personal recommendations for treatment of what often constitute complex Reproductive Issues.
If you wish to schedule an online consultation with me, please contact my assistant (Patti Converse) by phone (800-780-7437/702-533-2691), email (concierge@SherIVF.com) or, enroll online on then home-page of my website (www.SherIVF.com).
PLEASE SPREAD THE WORD ABOUT SFS!
Geoff Sher